Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Interest & Investment Income (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Interest & Investment Income for 9 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest & Investment Income rose 16.22% to $4.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.3 million, a 3.95% increase, with the full-year FY2025 number at $15.3 million, up 3.96% from a year prior.
  • Interest & Investment Income was $4.1 million for Q4 2025 at Rhythm Pharmaceuticals, down from $4.3 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $4.3 million in Q3 2025 to a low of $21000.0 in Q2 2021.
  • A 5-year average of $2.4 million and a median of $3.2 million in 2023 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: plummeted 86.44% in 2021, then surged 2169.4% in 2022.
  • Rhythm Pharmaceuticals' Interest & Investment Income stood at $134000.0 in 2021, then soared by 2169.4% to $3.0 million in 2022, then rose by 25.55% to $3.8 million in 2023, then dropped by 7.94% to $3.5 million in 2024, then increased by 16.22% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Interest & Investment Income are $4.1 million (Q4 2025), $4.3 million (Q3 2025), and $3.2 million (Q2 2025).